[Systemic collateral effects of intermittent antituberculous treatments with rifampicin].
D000614:Aminocaproates / Q000008:administration & dosage; D001247:Asthenia / Q000139:chemically induced; D004342:Drug Hypersensitivity / Q000150:complications; D005260:Female; D005334:Fever / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced
D000614:Aminocaproates; D012293:Rifampin
Effects collatéraux systémiques des traitements antituberculeux intermittents par la rifampicine.